Saturday 17 October 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,125.0%, EPS fell 66.7% and free cash flow fell 67.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
59.79
2.07
−3.35%
Follow CGON
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
Piotroski F-Score |
2 | 5 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
49.04 | 50.47 | — | — |
P/S ratio |
713.89 | 1,573.67 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
23.13 | 40.36 | 1.52 | 2.09 |
Beneish M-Score |
— | 1.90 | (0.08) | — |
P/Operating CF |
(88.62) | (86.75) | (10.99) | (10.99) |
P/B ratio |
4.26 | 2.44 | 0.00 | 0.00 |
Price to Tangible BV |
4.33 | 2.44 | 0.00 | 0.00 |
EV/Sales |
551.48 | 935.83 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.19 | 0.19 |
EV/Operating CF |
(18.73) | (13.54) | 0.25 | 0.25 |
EV/FCF |
(18.72) | (13.50) | 0.25 | 0.25 |
Quick Ratio |
24.09 | 34.76 | 13.17 | 9.32 |
Current Ratio |
24.63 | 35.30 | 13.62 | 9.54 |
Net Debt/EBITDA |
3.88 | 6.20 | 3.22 | 3.64 |
Debt/Assets |
0.38% | 0.00% | 0.00% | 10.49% |
Debt/Equity |
0.00 | 0.00 | 0.00 | (0.20) |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.82 | 0.89 | 0.67 | 0.68 |
Capex/Depreciation |
(0.31) | 0.05 | 0.00 | (0.24) |
| (21.67%) | (28.85%) | 67.53% | 0.00% | |
| (20.82%) | (18.45%) | (39.07%) | 0.00% | |
ROIC |
(886.69%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(21.63%) | (12.01%) | (37.68%) | (33.21%) |
Average Days of Receivables |
62.16 | 250.28 | 164.61 | 579.03 |
Research and Development Expense of Revenue |
2,887.15% | 7,208.25% | 22,427.45% | 15,198.43% |
Selling, General and Administrative Expense of Revenue |
1,819.95% | 2,959.00% | 4,853.43% | 3,354.97% |
Intangible Assets out of Total Assets |
0.01 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
660.30% | 1,001.05% | 749.02% | 353.93% |
Graham Net Nets |
0.22 | 0.41 | (0.80) | (0.80) |
Graham Number |
0.00 | 0.00 | 84.72 | 0.00 |
Earnings Yield |
(4.99%) | (4.95%) | (30.19%) | (30.19%) |
Free Cash Flow Yield |
(4.13%) | (4.40%) | (28.38%) | (28.38%) |
Revenue per Share |
0.05 | 0.02 | 0.05 | 0.05 |
Operating CF per Share |
(1.71) | (1.26) | (10.55) | (7.97) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.71) | (1.26) | (10.55) | (7.97) |
Cash per Share |
9.60 | 11.87 | 43.33 | 38.35 |
Shareholders Equity per Share |
9.74 | 11.73 | (28.42) | (20.77) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.74 | 11.73 | (28.42) | (20.77) |
Free Cash Flow |
(132.48) | (78.95) | (45.68) | (29.82) |
Working Capital |
728.64 | 732.84 | 179.87 | 131.78 |
Capital Expenditures |
(0.13) | (0.23) | — | (0.01) |
Net Current Asset Value |
720.49 | 732.79 | (128.28) | (78.23) |
EV/EBIT |
0.00 | 0.00 | 0.20 | 0.20 |
Capex to Sales |
0.03 | 0.21 | 0.00 | 0.07 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.03 | (18.24) | (40.84) | 0.69 |
Cash ROIC |
(8.85%) | (5.35%) | (70.74%) | (36.68%) |
Accounts Receivable Turnover |
5.50 | 2.61 | 1.03 | 0.00 |
Accounts Payable Turnover |
0.76 | 0.00 | 0.00 | — |
Inventory Turnover |
0.00 | — | — | — |
Average Days of Payables |
448.81 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
122.92 | — | — | — |
Average Receivables |
0.73 | 0.44 | 0.20 | — |
Average Payables |
6.12 | 4.88 | 2.11 | — |
Average Assets |
773.19 | 477.05 | 173.52 | — |
Average Common Equity |
742.99 | 305.14 | (100.40) | — |
Columns are period end dates